Biodesix, Inc. (NASDAQ:BDSX) Director Matthew Strobeck Purchases 558,659 Shares

Biodesix, Inc. (NASDAQ:BDSXGet Rating) Director Matthew Strobeck bought 558,659 shares of the business’s stock in a transaction on Thursday, April 7th. The stock was bought at an average price of $1.79 per share, with a total value of $999,999.61. The purchase was disclosed in a filing with the SEC, which is available at this link.

Biodesix stock opened at $1.66 on Thursday. The business’s fifty day simple moving average is $2.41 and its two-hundred day simple moving average is $4.77. Biodesix, Inc. has a 12 month low of $1.56 and a 12 month high of $19.75. The company has a market capitalization of $51.97 million, a price-to-earnings ratio of -1.06 and a beta of 2.27.

Biodesix (NASDAQ:BDSXGet Rating) last released its earnings results on Monday, March 14th. The company reported ($0.49) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.49). During the same period in the prior year, the company earned ($0.25) earnings per share. On average, equities analysts expect that Biodesix, Inc. will post -1.13 EPS for the current fiscal year.

A number of analysts recently weighed in on the company. Zacks Investment Research downgraded Biodesix from a “buy” rating to a “hold” rating in a research report on Thursday, March 17th. Canaccord Genuity Group reduced their target price on Biodesix from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, February 15th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $15.35.

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in Biodesix by 3.5% in the third quarter. Geode Capital Management LLC now owns 151,023 shares of the company’s stock worth $1,241,000 after acquiring an additional 5,064 shares in the last quarter. Avidian Wealth Solutions LLC lifted its holdings in shares of Biodesix by 56.3% during the third quarter. Avidian Wealth Solutions LLC now owns 50,000 shares of the company’s stock valued at $411,000 after purchasing an additional 18,000 shares in the last quarter. Trexquant Investment LP lifted its holdings in shares of Biodesix by 58.8% during the third quarter. Trexquant Investment LP now owns 18,857 shares of the company’s stock valued at $155,000 after purchasing an additional 6,983 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Biodesix by 33.1% during the second quarter. Goldman Sachs Group Inc. now owns 15,547 shares of the company’s stock valued at $205,000 after purchasing an additional 3,863 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in shares of Biodesix by 363.2% during the second quarter. Morgan Stanley now owns 43,604 shares of the company’s stock valued at $575,000 after purchasing an additional 34,190 shares in the last quarter. 75.82% of the stock is currently owned by institutional investors and hedge funds.

About Biodesix (Get Rating)

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

Featured Stories

Insider Buying and Selling by Quarter for Biodesix (NASDAQ:BDSX)

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.